Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

64.79 +0.20 (+0.31%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,616,436
Open 64.59
Bid (Size) 64.57 (3)
Ask (Size) 65.05 (1)
Prev. Close 64.59
Today's Range 64.36 - 65.06
52wk Range 61.73 - 76.56
Shares Outstanding N/A
Dividend Yield 1.44%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments
LianBio received a $465 million buyout offer from Tang Capital Management. In addition, Tang also offered shareholders a contingent value right for 80% of net proceeds from any license or divestment of... 
Via Talk Markets
Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers
European Medicines Agency (EMA) will request further clarifications from drugmakers of GLP-1 receptor agonists for diabetes and weight loss, including Novo Nordisk A/S's (NYSE: NVO) popular therapies... 
Via Benzinga

Performance

YTD
-6.55%
-6.55%
1 Month
+0.95%
+0.95%
3 Month
-4.21%
-4.21%
6 Month
-13.17%
-13.17%
1 Year
-5.37%
-5.37%

More News

Read More
AstraZeneca Stops Two Lokelma Late-Stage Trials After Evaluating Potential Benefits
Via Benzinga
AstraZeneca advances scientific leadership in hematology at ASH 2023
From AstraZeneca
Via Business Wire
Industry Comparison: Evaluating AstraZeneca Against Competitors In Pharmaceuticals Industry
Via Benzinga
Investigating AstraZeneca's Standing In Pharmaceuticals Industry Compared To Competitors
Via Benzinga
Week In Review: BeiGene Signs $1.3 Billion Deal For Preclinical CDK2 Inhibitor From Boston’s Ensem
Via Talk Markets
Eli Lilly and Novo Nordisk Are Big Names in Weight Loss, but Investors Shouldn't Count Out This Healthcare Giant
Via The Motley Fool
3 No-Brainer Stocks to Buy With $1,000 Right Now
Via The Motley Fool
5 Growth Stocks to Buy for 2024
Via InvestorPlace
AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes
From AstraZeneca
Via Business Wire
3 stocks that crushed earnings estimates and still tanked
Via MarketBeat
Exposures COVID-19
US CDC Rolls Out Additional Doses For Sanofi/AstraZeneca Recently Approved Respiratory Infection Drug As Demand Surges
Via Benzinga
AstraZeneca Is Trying to Make an Ozempic Competitor (Again), but Don't Rush to Buy the Stock
Via The Motley Fool
FDA Approves AstraZeneca's Truqap/Faslodex Combo Therapy For Breast Cancer, Competes With Gilead's Drug
Via Benzinga
Exposures Product Safety
TRUQAP™ (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive breast cancer
From AstraZeneca
Via Business Wire
FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca
Via Benzinga
Exposures Product Safety
AstraZeneca's Flagship Cancer Drug Imfinzi Fails On Main Goal In Lung Cancer Trial When Combined With Chemoradiotherapy
Via Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes $200 Billion GLP-1 Market with its DehydraTECH(TM) Technology
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Royal Rule: Buy These 3 Dividend Aristocrats on Every. Single. Dip.
Via InvestorPlace
Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal
Via Talk Markets
The 7 Next Trillion Dollar Companies to Invest in to Become a Millionaire
Via InvestorPlace
AstraZeneca Plc (AZN) Q3 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Auto Trader & AstraZeneca Help FTSE Reverse Early Losses
Via Talk Markets
AstraZeneca Is Making A $2 Billion Bet To Rival Lilly, Novo In Obesity Drugs
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback